About this trial
This study capitalizes on the emerging technology of 19F MRI, using conventional 'thermally' polarized perfluorinated gas (perfluoropropane, or PFP) mixed with oxygen and studied with magnetic resonance imaging (MRI) to visualize ventilation. This technique has not been studied in children.
Children and adolescents (6-17 years old) with cystic fibrosis (CF) who have normal spirometry will undergo 19F MRI with the inhalation of an inert contrast gas to study ventilation. Comparisons will be made to a cohort of healthy children (6-17 years old) who will perform the same measures. The primary outcome measure is the feasibility of conducting these studies in the pediatric population. Parallel performance of multiple breath nitrogen washout (MBW) and spirometry will be used to compare the sensitivity of these outcomes to the presence of mild lung disease in these children. Finally, the investigators will compare data obtained during standard breath holds with a novel "free-breathing" technique that will eliminate the need for breath holds during MRI acquisition.
Eligibility criteria
Qualifiers
6-17 years old
Non-smoker and non-vaper
Cystic Fibrosis (CF) Group: must have a diagnosis of CF
No use of supplemental oxygen
Disqualifiers
Healthy volunteers: with any history of chronic lung disease (i.e. asthma)
Active or former smoker with less than 1 year of quitting
Injury to the eye involving a metallic object
Injury to the body involving a metallic object
Trial design
Treatments tested in this trial
- 19F MRI
Treatment groups
Sponsors and collaborators
University of North Carolina, Chapel Hill
Lead sponsor
Cystic Fibrosis Foundation
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator